canrenone
Trade name: Contaren
Small moleculeexperimental
Potassium canrenoate or canrenoate potassium (USAN), also known as aldadiene kalium, the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group. Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body. — Wikipedia
Clinical trial activity
8 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
4
Earliest trial started Sep 1, 2002 (NCT00403910)
Timeline
Indications
Approved for
Mechanism of action
- Mineralocorticoid receptorANTAGONIST
NR3C2 antagonist
Canrenone specifically antagonizes aldosterone at the mineralocorticoid receptor in the kidneys, thereby increasing sodium excretion and inhibiting potassium excretion.
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)O- Mol. weight
- 358.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1616951 ↗
- WikipediaPotassium canrenoate ↗
- ChEMBLCHEMBL1463345 ↗
- ChEMBLCHEMBL1371200 ↗
- WikipediaCanrenone ↗
Also known as
- aldadiene
- aldadiene kalium
- aldadiene potassium
- canrenoate
- canrenoate
- canrenoate
- canrenoate
- canrenoate potassium
- canrenoate potassium
- canrenoate potassium
- canrenoic acid
- canrenoic acid
- canrenoic acid
- canrenoic acid
- canrenoic acid potassium
- canrenoic acid potassium salt
- canrenone
- canrenone
- canrenone
- canrenone
- canrenone
- canrenone
- canrenone
- canrenone
- canrenone
- kanrenol
- phanurane
- potassium canrenoate
- potassium canrenoate
- potassium canrenoate
- potassium canrenoate
- potassium canrenoate
- potassium canrenoate
- potassium canrenoate
- potassium canrenoate
- sc-14266
- sc-14266
- sc-9376
- sc-9376
- soldactone
- soldactone
- spiroctan-m
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05411991 | Phase 4 | Jun 12, 2022 | Free University of Brussels, Hasselt University, Roche |
| NCT04977960 | Phase 2 | Sep 30, 2021 | A.O. Ospedale Maggiore di Lodi, University of Bologna, University of Milan |
| NCT04714710 | Phase 2 | Aug 26, 2021 | CHU Brabois, University of Lorraine |
| NCT04912011 | Phase 4 | Jan 1, 2021 | Pomeranian Medical University |
| NCT03536806 | Phase 4 | Jun 30, 2018 | Medical University of Warsaw |
| NCT01882179 | Phase 3 | Nov 1, 2013 | Basildon and Thurrock University Hospitals NHS Foundation Trust, British Heart Foundation, University of Leeds, University of London |
| NCT02687178 | Phase 4 | Oct 1, 2010 | University of Pavia |
| NCT00403910 | Phase 3 | Sep 1, 2002 | Heart Care Foundation, University of Brescia |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| A.O. Ospedale Maggiore di Lodi | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Basildon and Thurrock University Hospitals NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2013 |
| British Heart Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| CHU Brabois | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Free University of Brussels | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Hasselt University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Heart Care Foundation | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Medical University of Warsaw | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Pomeranian Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Roche | For profit | 1 | 0 | 1 | 2022 |
| University of Bologna | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Brescia | Academic/Hospital | 1 | 0 | 1 | 2002 |
| University of Leeds | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Lorraine | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Milan | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Pavia | Academic/Hospital | 1 | 1 | 1 | 2010 |
17 organizations
Page 1 / 1